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Abstract
Objective—To assess the vision-related quality of life in a cohort of patients with ocular graft-
versus-host disease (GVHD).
Design—Prospective study.
Participants—Eighty-four patients diagnosed with chronic ocular GVHD
Methods—We assessed the vision-related quality of life with the 25-item National Eye Institute 
Visual Function Questionnaire (NEI-VFQ-25). The symptoms of ocular GVHD were assessed 
using the Ocular Surface Disease Index (OSDI) and Symptom Assessment in Dry Eye (SANDE) 
questionnaires.
Main outcome measures—We assessed vision-related quality of life with NEI-VFQ-25 and 
compared the scores obtained from patients with ocular GVHD to those from a healthy population. 
In the ocular GVHD population, we also evaluated the associations between the NEI-VFQ-25 and 
dry eye symptoms measured by OSDI and SANDE questionnaires, age, duration of disease, best-
corrected visual acuity, corneal fluorescein staining, tear break-up time, and Schirmer test.
Results—The mean composite NEI-VFQ-25 score in patients with ocular GVHD was 76.5 ± 17. 
Compared to healthy subjects, ocular GVHD patients reported reduced scores on all NEI-VFQ-25 
subscales (each P < 0.001) with exception of color vision (P = 0.11). The NEI-VFQ-25 composite 
scores significantly correlated with OSDI (R = −0.81, P < 0.001), SANDE (R = −0.56, P < 0.001), 
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corneal fluorescein staining (R = −0.36, P = 0.001) and best-corrected visual acuity (R = −0.30, P 
= 0.004).
Conclusion—Patients with ocular GVHD experience measurable impairment of vision-related 
quality of life. This study highlights the impact of ocular GVHD on the vision-related quality of 
life, and hence the importance of comprehensive diagnosis and treatment of this condition.
Introduction
Allogeneic hematopoietic stem cell transplantation (HSCT) is a potentially curative 
treatment for various malignant and non-malignant hematological disorders. Medical 
advances have increased the frequency of transplants and survival rates,1,2 and long-term 
complications after HSCT have consequently become key determinants of the overall 
quality of life in these patients. Graft-versus-host disease (GVHD), a condition occurring 
after allogeneic HSCT when donor-derived immune cells recognize and attack the recipient 
tissues,3 is a major cause of morbidity that compromises patients’ quality of life (QOL).4 
Manifestations of graft-versus-host disease can be seen in various organs including skin, 
gastrointestinal tract, liver, lungs, oral mucosa, or eyes.5
Ocular involvement presents in 40-60% of patients undergoing allogeneic HSCT.6 Ocular 
GVHD generally manifests as dry eye disease with symptoms of ocular discomfort, pain, 
redness, grittiness, and blurred vision. The clinical signs include conjunctival hyperemia, 
corneal epitheliopathy, meibomian gland dysfunction, conjunctival and corneal scarring, 
stromal ulceration, and symblepheron.7,8 Dry eye disease has been shown to affect quality of 
life in other settings, but there is limited information regarding the impact of manifestations 
of ocular GVHD on vision-related quality of life.9-12
The 25 item National Eye Institute Visual Function Questionnaire (NEI-VFQ-25) is used to 
assess patients’ perceptions of their visual function and the impact of an eye disease on their 
quality of life.13 The NEI VFQ-25 has been used to assess vision-related quality of life in 
various eye diseases such as cataract, macular degeneration, glaucoma, ocular chemical 
burns, diabetic retinopathy, uveitis, dry eye disease, and low vision.11,14-18 The purpose of 
this study was to evaluate vision-related quality of life in a large cohort of patients with a 
diagnosis of ocular GVHD using the NEI-VFQ-25. Additionally, we evaluated the 
association between the measured quality of life and the signs and symptoms of ocular 
GVHD.
Methods
One hundred consecutive patients with ocular GVHD examined at the Cornea Service, 
Massachusetts Eye and Ear Infirmary, Boston MA, were included in this prospective study. 
The study was approved by the Institutional Review Board and followed the tenets of the 
Declaration of Helsinki. Informed consent was obtained from all patients. The inclusion 
criteria required patients to have a diagnosis of chronic ocular GVHD confirmed by an 
ophthalmologist, be older than 18 years, and comprehend the English language. All the 
patients satisfied the National Institutes of Health (NIH) criteria for diagnosis of ocular 
GVHD, which require a distinctive affectation of chronic GVHD in an organ different than 
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the eye accompanied by one of the following ocular manifestations: 1) new ocular sicca 
documented with a bilateral Schirmer test averaging ≤ 5 mm, or 2) a new onset of ocular 
sicca by slit-lamp examination with a bilateral Schirmer test averaging 6-10 mm.5
All the participants self-responded the NEI-VFQ-25 questionnaire once the basic 
instructions were provided by the research staff.13 This questionnaire consists of 25 vision-
targeted questions representing 11 subscales that include: general vision, difficulty with near 
vision activities, difficulty with distance vision activities, ocular pain, limitations in social 
functioning due to vision, role limitations due to vision, dependency on others due to vision, 
mental health symptoms due to vision, driving difficulties, limitations with peripheral 
vision, and color vision. Additionally the NEI-VFQ-25 includes one question that assesses 
the patient’s general health. The overall composite score for the NEI-VFQ-25 is calculated 
by averaging the scores of all the subscales with the exception of the general health 
question. The score of each subscale is represented by the average of the responses to 
questions answered in each subscale section. Both the composite and subscale scores range 
from 0 to 100, where higher scores indicate better quality of life.
Symptoms of ocular surface disease were assessed with the following two questionnaires: 
Ocular Surface Disease Index (OSDI) and Symptom Assessment in Dry Eye (SANDE).19,20 
The OSDI questionnaire consists of 12 questions measuring the frequency of dry eye 
symptoms, visual impact of dry eye, and triggers; each question was graded on a scale from 
0 (“none of the time”) to 4 (“all of the time”). The total OSDI score was calculated 
according to the questionnaire’s algorithm with a total score ranging from 0 to 100 where 
higher scores indicate greater disability.20 The SANDE questionnaire comprises two 
questions measuring the frequency and severity of dry eye symptoms; each of these two 
items were assessed on a 100 mm visual analog scale and scored from 0 to 100. The total 
SANDE score was calculated as the square-root of the product of the two item scores, and 
ranges from 0 to 100 with higher scores indicating greater disability.19 Additionally, we 
recorded the time of hematopoietic stem cell transplantation, duration of ocular GVHD, and 
assessed the following clinical parameters at the same visit when the questionnaires were 
administered: Snellen best-corrected visual acuity (BCVA), Schirmer I test with anesthesia, 
tear break-up time (TBUT), and corneal fluorescein staining (CFS; National Eye Institute 
grading system).21 We excluded 16 patients who had other ocular comorbidities unrelated to 
ocular GVHD that could potentially affect visual function, such as cataract with BCVA of 
20/30 or worse (8 patients), glaucoma (1), macular or retinal disorders (4), amblyopia (1), 
hemianopia (1), and intraocular surgery within one month (1). There were no patients with 
any history of refractive surgery.
Data are presented as the mean ± standard deviation (SD) and range for continuous 
variables, and percentages for categorical variables. The NEI-VFQ-25 composite and 
subscale scores were computed according to the published algorithms.22 The NEI-VFQ-25 
subscale mean scores from patients with ocular GVHD were compared to the mean scores of 
122 healthy subjects from the original NEI-VFQ-25 developmental work using the Welch’s 
unpaired t-test.13 The healthy control population included 75 women (62%) and 47 men 
(38%) older than 21 years (mean 59±14), with no evidence of underlying eye disease other 
than refractive errors correctable to ≥20/25 in the worse eye. The median visual acuity in the 
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better eye was 20/20 (range 20/13-20/100).13,16 We evaluated the association of the QOL 
scores with patients’ age, dry eye symptoms, duration of ocular GVHD; and with the 
average of both eyes for best-corrected visual acuity, corneal fluorescein staining, tear 
break-up time, and Schirmer test using the Spearman’s coefficient of correlation. Visual 
acuities were measured with a standardized Snellen chart and converted to LogMAR values 
at the time of the analysis. A two-sided P value of < 0.05 was considered statistically 
significant.
Results
The final analysis included 84 patients (56 men and 28 women) with a mean age of 56 ± 12 
years (range 22 to 74). The patients’ transplant characteristics are shown in Table 1. The 
mean BCVA, average of both eyes, was 0.08 ± 0.13 LogMAR (Snellen equivalent 20/24, 
median 20/22, range 20/20-20/150) and the mean BCVA in the better eye was 0.04 ± 0.09 
LogMAR (Snellen 20/22, median 20/20, range 20/20-20/60). The mean dry eye clinical 
signs were: Schirmer test 4.5 ± 3.6 mm (range 0-12.5), TBUT 2.6 ± 2.3 seconds (range 
0-9.5), and CFS 6.3 ± 4.4 (range 0-15). The mean OSDI score was 42.5 ± 24.1 (range 0-94) 
and the mean SANDE score was 52.2 ± 24.2 (range 0-95). The mean NEI-VFQ-25 
composite and subscale scores are shown in Table 2. The mean composite score was 76.5 ± 
17 (18-98). The comparison between the mean subscales’ scores in patients with ocular 
GVHD and the healthy population of reference is shown in Figure 1. The mean age between 
the studied GVHD population (56 ± 12) and the reference population (59 ± 14) was 
comparable (P = 0.11). With the exception of color vision, the patients with ocular GVHD 
presented with significantly lower scores on all NEI-VFQ-25 subscales when compared to 
the reference population (P < 0.001). The subscales that scored particularly low (less quality 
of life) with a difference of more than 10 points as compared to the healthy subjects were: 
ocular pain, vision specific role limitations, vision specific mental health symptoms, 
difficulty with near vision, distance vision, general vision activities, vision specific 
dependency, peripheral vision, and general health.
OSDI and SANDE questionnaires showed a statistically significant correlation with the 
NEI-VFQ-25 composite score (Figure 2; OSDI: R = −0.81, P < 0.001, SANDE: R= −0.56, P 
< 0.001); and with the majority of the QOL subscales’ scores (Table 3), showing a 
significant association between increased dry eye symptoms and decreased quality of life 
scores. Among the dry eye clinical parameters, there was a modest but statistically 
significant correlation between the NEI-VFQ-25 composite score and corneal fluorescein 
staining (Figure 2; R = −0.36, P = 0.001). CFS also correlated significantly with most 
subscales of the NEI-VFQ-25 (Table 3), showing that increased corneal fluorescein staining 
is associated with reduced quality of life scores. The best-corrected visual acuity was also 
statistically significantly correlated with the quality of life composite score (Figure 2; R = 
−0.30, P = 0.004) and with the majority of the NEI-VFQ-25 subscales (Table 3). Schirmer 
test and TBUT were not correlated with the quality of life scores (Figure 2, Table 3). There 
was no correlation between the composite quality of life score and patients’ age (R = 0.15, P 
= 0.15) or duration of ocular GVHD (R = 0.01, P = 0.85). Correlations adjusted for age and 
sex are presented as supplementary data in table 4 (available at http://www.aaojournal.org).
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The present study demonstrates that patients with ocular GVHD experience significant 
impairment in vision-related quality of life when compared to the healthy population. We 
found that patients’ vision-related quality of life is strongly associated with symptoms of 
ocular dryness, and modestly associated with the degree of corneal epitheliopathy.
Ocular GVHD presents mainly with dry eyes and ocular surface inflammation and, 
unsurprisingly, ocular pain was the most affected variable among the eleven subscales of the 
NEI-VFQ-25 questionnaire. This observation is in accordance with previous reports on QOL 
in dry eye disease.11,23,24 The mean scores in the subscales of role difficulties, near vision 
activities, distance vision activities, general vision, dependency, vision specific mental 
health, and peripheral vision, were particularly low with a difference of more than 10 points 
when compared to the mean scores in the healthy reference population.13 Additionally, a 
study from 2012, reported a mean composite QOL score of 94 in a cohort of 71 healthy 
controls.11 A difference of 5 to 10 points in the NEI-VFQ-25 has been reported to be 
clinically significant in previous studies.25,26 The low scores on the different subscales 
suggest that, beyond the ocular discomfort from the ocular surface disease, patients with 
ocular GVHD experience significant problems with various activities of the daily living. 
Riemans et al. showed significantly decreased scores in ocular pain, role difficulties, general 
vision, and social functioning in 14 patients with ocular GVHD compared to post-HSCT 
patients without ocular GVHD.12 Our observations in a larger cohort of 84 patients confirm 
these observations and additionally show a severe effect on the vision-related mental health 
subscale, with a difference of 25 points compared to healthy subjects. Vision-related mental 
health is assessed by questions regarding worry and frustration because of the patient’s eye 
problems. Our finding is in accord with previous reports of impaired mental health, anxiety 
and depression scores in patients with dry eye disease,11,23 and perhaps suggests the 
potential benefit of patient counseling as part of a comprehensive management of ocular 
GVHD.
Our results demonstrate that the composite quality of life score in patients with ocular 
GVHD (score 76.5) is impaired to a similar degree as has been observed among patients 
with Sjogren’s syndrome related dry eye (73).27 The ocular pain observed in this study (61) 
was comparable to pain scores reported in patients with ocular chemical burns (58) 
evidencing the severity of the ocular discomfort experienced by these patients.15 Other 
ocular conditions in which the NEI-VFQ-25 QOL composite score has been used to assess 
vision-related quality of life are: posterior subcapsular cataract (score 81),28 open angle 
glaucoma (84),28 dry eye disease (88, 82, 85),24,29,30 age-related macular degeneration 
(73),31 macular telangiectasia (77),32 proliferative diabetic retinopathy (83),33 diabetic 
macular edema (83),33 anterior herpetic uveitis (88),34 ocular chemical burns (40),15 and 
Steven Johnson syndrome (49).35 The subscales related to role difficulties, mental health 
and dependency in patients with ocular GVHD show either comparable or more severely 
affected scores than other incapacitating eye diseases such as glaucoma, cataract, anterior 
herpetic uveitis, and branch retinal vein occlusion.13,34,36 This observation highlights the 
extent of the limitations experienced by patients with ocular GVHD performing vision-
demanding activities.
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We noted a strong association between the NEI-VFQ-25 and the OSDI scores (R = −0.81) 
and a moderate association between the NEI-VFQ-25 and the SANDE scores (R = −0.56). 
The OSDI is perhaps the most commonly used dry eye questionnaire to measure symptoms 
of ocular surface disease. Although the OSDI is considered as an ocular surface disease-
specific symptom questionnaire, it gathers additional information regarding limitations in 
performing common vision-related activities. Some of the OSDI questions address topics 
related to those in the NEI-VFQ-25, and this may explain the strong correlation between the 
two scales. Vitale et al. reported a moderate correlation between the OSDI and NEI-VFQ-25 
(R= −0.61) in patients with Sjogren’s syndrome.37 The present findings confirm that the 
OSDI not only provides dry eye symptom information, but may also provide valuable 
information to judge the overall vision-related QOL in patients with ocular GVHD. This is 
particularly important since quality of life is not commonly evaluated and thus clinicians 
could utilize the OSDI to indirectly infer their patients’ quality of life. The SANDE 
questionnaire is a short and sensitive tool to assess dry eye symptoms,38 and the lower 
degree of correlation between the SANDE and NEI-VFQ composite score (R = −0.56), as 
compared to OSDI, is likely because the SANDE scale is designed to measure ocular surface 
discomfort symptoms and not other activities of daily living.
Corneal epitheliopathy, measured by corneal fluorescein staining, is the only dry eye clinical 
parameter that significantly correlates with the QOL composite score and the majority of its 
subscales. Since a smooth corneal surface and a stable tear film are critical factors in 
forming clear images,39 the epithelial damage caused by ocular surface disease leading to 
corneal surface irregularities may cause optical disturbances that impair visual function.40 A 
modest level of association between CFS and OSDI scores was previously reported by our 
group,41 and by Le et al.,23 who also noted a significant association between CFS and the 
composite NEI-VFQ-25 QOL score. These findings would suggest that therapeutic 
strategies that effectively target corneal fluorescein staining could lead to an improvement of 
vision-related quality of life in these patients. The pathophysiology of ocular GVHD 
involves an immune reaction of the transplanted cells against the host tissue, which leads to 
inflammation in the conjunctiva and lacrimal and meibomian glands, therefore manifesting 
with dry eye syndrome features.7 Hence, our data linking CFS to reduced vision-related 
quality of life in patients with ocular GVHD may be applicable to other types of dry eye.
A limitation of this study entails, arguably, the patients’ incapacity to fully discriminate 
between their perception of disability from multiple systemic affectations and the ocular 
disease. Although the NEI-VFQ-25 is designed to evaluate the vision-related quality of life, 
it relies on patients’ perception of disability and patients undergoing bone marrow 
transplantation have several systemic health conditions that may also influence their 
responses. In this study, we lacked a control group and relied on the data from the NEI-
VFQ-25 developmental study control group, as other investigators have done 
previously.14,17,18,32,42 The main objective of this manuscript is to describe the vision-
related quality of life in patients with ocular GVHD, thus comparing their QOL scores with 
healthy subjects from a historical healthy control group was intended only to provide context 
for interpretation of the observed QOL scores in patients with ocular GVHD. Due to the 
nature of such comparisons (using summary rather than individual data), some possible 
differences between these populations could not be directly accounted for, and hence results 
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from this comparison should be interpreted with caution. It would also be of interest to 
compare QOL indicators among groups of GVHD patients with different morbidities. A 
limitation of some questionnaires that rely on patients’ perception of symptoms, such as the 
NEI-VFQ-25, is their incapacity to assess further improvement in patients who reach near 
the maximum score despite considerable disease. Therefore, after clinical recovery (e.g., 
after treatment) the room for further score improvement is limited, this ceiling effect was 
present in some of the patients evaluated in this study.
In summary, this study shows that patients with chronic ocular GVHD experience 
significant impairment in multiple domains of vision-related quality of life as compared to 
the healthy population of reference. Strong associations are noted between symptoms of 
ocular surface disease and vision-related quality of life, while corneal fluorescein staining is 
modestly associated with quality of life scores. The findings from this study reveal the great 
impact of ocular GVHD on the vision-related quality of life and highlight the multiple facets 
of dysfunction faced by survivors after bone marrow transplantation.
Supplementary Material
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Patients with ocular graft-versus-host disease experience significant impairment of 
vision-related quality of life compared with healthy controls. Additionally, symptoms of 
dry eye and corneal epitheliopathy show significant correlation with the quality of life 
measurements.
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Comparison of the mean National Eye Institute Visual Function Questionnaire-25 scores 
between ocular graft-versus-host disease patients (n = 84) and a healthy reference population 
from the article by Mangione et al.13 (n = 122). VS: vision-specific. P value was < 0.001 in 
all the subscales except for the color vision subscale (P = 0.11).
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Correlations of the National Eye Institute Visual Function Questionnaire-25 (NEI-VFQ-25) 
score with the clinical symptoms and signs. OSDI: Ocular Surface Disease Index; SANDE: 
Symptoms Assessment in Dry Eye; TBUT: tear break-up time; BCVA: best corrected visual 
acuity; LogMAR: logarithm of minimum angle of resolution; R: Spearman’s correlation 
coefficient. Higher scores in the NEI-VFQ-25 indicate better quality of life (note the 
negative correlations with OSDI, SANDE, corneal fluorescein staining, and BCVA).
Saboo et al. Page 12

















Saboo et al. Page 13
Table 1
Characteristics of the study population
Characteristic
Age mean ± SD years 56 ± 12
Gender (%)
 Male 56 (67)
 Female 28 (33)
Primary Disorder (%)
 Acute myeloid leukemia 33 (39)
 Acute lymphoid leukemia 6 (7)
 Chronic myeloid leukemia 5 (6)
 Chronic lymphoid leukemia 10 (12)
 Myelodysplastic syndrome 11 (13)
 Non-Hodgkin Lymphoma 13 (16)
 Hodgkin Lymphoma 1 (1)
 Multiple myeloma 3 (4)
 Others 2 (2)
Duration since HSCT in days mean ± SD 1348 ± 1002
Duration since diagnosis of ocular GVHD in days mean ± SD 873 ± 955
SD: standard deviation; HSCT: hematopoietic stem cell transplantation; GVHD: graft-versus-host disease.
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Table 2
25-item National Eye Institute Visual Function Questionnaire Scores in Patients with Ocular Graft-versus-host 
Disease
Subscale (no. of questions in
each subscale) Mean ± SD Range
Composite Score 76.5 ± 17 18-98
 Ocular pain (2) 60.8 ± 24 0-100
 VS Role difficulties (2) 64.5 ± 31 0-100
 VS Mental health (4) 67.2 ± 26 6-100
 General vision (1) 69.1 ± 16 20-100
 Near activities (3) 69.6 ± 21 17-100
 Distance activities (3) 77.1 ± 21 8-100
 Driving* (3) 76.9 ± 21 0-100
 VS Dependency (3) 85.3 ± 24 8-100
 Peripheral vision (1) 85.4 ± 23 0-100
 VS Social functioning (2) 90.1 ± 18 13-100
 Color vision (1) 94.9 ± 16 0-100
General Health (1) 46.7 ± 22 0-100
Score range from 0 to 100 (where 100 represent the best quality of life). VS: vision specific.
*Six participants did not drive for reasons other than vision difficulties.
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Table 3
Correlations of NEI-VFQ-25 Scores with Symptoms and Clinical Parameters in patients with Ocular Graft-
versus-host Disease
NEI-VFQ-25 Scales OSDI SANDE CFS TBUT Schirmer BCVA
Composite score
−0.8* −0.6* −0.4* 0.2 0.2 −0.3*
Ocular pain
−0.7* −0.6* −0.3* 0.2 0.1 −0.2
VS Role difficulties
−0.6* −0.5* −0.2 0.2 0.1 −0.2*
VS Mental function
−0.8* −0.5* −0.4* 0.2 0.2 −0.3*
General vision
−0.5* −0.2* −0.4* 0.1 0.1 −0.3*
Near activities
−0.7* −0.5* −0.4* 0.1 0.2 −0.2*
Distance activities
−0.6* −0.6* −0.3* 0.1 0.1 −0.4*
Driving
−0.4* −0.2 −0.2 0.1 0.2 −0.3*
VS Dependency
−0.6* −0.4* −0.3* 0.1 0.0 −0.2
Peripheral vision
−0.4* −0.2* −0.1 0.1 −0.1 −0.2
VS Social function
−0.5* −0.5* −0.1 0.1 0.0 −0.3*
Color vision
−0.3* −0.2* −0.0 −0.1 −0.1 −0.1
General Health −0.2 −0.2 −0.0 0.1 −0.1 −0.1
NEI-VQ-25: 25-item National Eye Institute Visual Function Questionnaire; SANDE: Symptoms Assessment in Dry Eye; OSDI: Ocular Surface 
Disease Index; CFS: corneal fluorescein staining; TBUT: tear break-up time; BCVA: best-corrected visual acuity; VS: vision specific. Higher 
scores in the NEI-VFQ-25 indicate better quality of life (note the negative correlations with OSDI, SANDE, CFS, and BCVA).
*
P<0.05
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